Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Receptors Chimeric Antigen”

887 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 887 results

Early research (Phase 1)Looking for participantsNCT07007117
What this trial is testing

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

Who this might be right for
Refractory NeuroblastomaRelapsed NeuroblastomaHigh-Risk Neuroblastoma
Stephan Grupp MD PhD 38
Not applicableUnknownNCT06041815
What this trial is testing

Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies

Who this might be right for
Hematological MalignanciesChimeric Antigen Receptor T-cell Therapy
The First Affiliated Hospital of Soochow University 100
Very early researchUnknownNCT04966143
What this trial is testing

Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Shanghai Longyao Biotechnology Inc., Ltd. 30
Testing effectiveness (Phase 2)Looking for participantsNCT06378190
What this trial is testing

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

Who this might be right for
Refractory B-Cell LymphomaB-cell Lymphoma Recurrent
Instituto de Investigación Biomédica de Salamanca 27
Not applicableUnknownNCT05414162
What this trial is testing

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

Who this might be right for
DLBCLMultiple MyelomaCytokine Release Syndrome+6 more
University Hospital, Bonn 60
Testing effectiveness (Phase 2)UnknownNCT05472610
What this trial is testing

Study of Efficacy of BZ019 in Large B-cell Lymphoma

Who this might be right for
Large B-cell Lymphoma
Shanghai Mengchao Cancer Hospital 36
Early research (Phase 1)WithdrawnNCT03904069
What this trial is testing

Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML

Who this might be right for
Relapsed/Refractory Acute Myeloid Leukemia
Amgen
Testing effectiveness (Phase 2)Study completedNCT04601831
What this trial is testing

'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL

Who this might be right for
Non-Hodgkin Lymphoma
University of Texas Southwestern Medical Center 14
Early research (Phase 1)WithdrawnNCT04094766
What this trial is testing

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Who this might be right for
Refractory B Acute Lymphoblastic LeukemiaRelapse B Acute Lymphoblastic Leukemia
Second Affiliated Hospital of Xi'an Jiaotong University
Early research (Phase 1)UnknownNCT03086954
What this trial is testing

Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma

Who this might be right for
Lymphoma
Sinobioway Cell Therapy Co., Ltd. 24
Early research (Phase 1)Looking for participantsNCT06185751
What this trial is testing

Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Washington University School of Medicine 25
Early research (Phase 1)UnknownNCT03114670
What this trial is testing

Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT

Who this might be right for
Adult Acute Myeloid Leukemia
Affiliated Hospital to Academy of Military Medical Sciences 20
Testing effectiveness (Phase 2)Looking for participantsNCT07473154
What this trial is testing

Controlling Hyperactive Immunity With Long-lived Lymphocytes

Who this might be right for
Diffuse Cutaneous Systemic SclerosisRheumatoid Arthritis (RA)Systemic Sclerosis (SSc)+1 more
Quell Therapeutics Limited 16
Early research (Phase 1)Looking for participantsNCT07224373
What this trial is testing

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
AstraZeneca 24
Testing effectiveness (Phase 2)WithdrawnNCT02723942
What this trial is testing

CAR-T Cell Immunotherapy for HCC Targeting GPC3

Who this might be right for
GPC3 Positive Hepatocellular CarcinomaCAR-T Cell Immunotherapy
Fuda Cancer Hospital, Guangzhou
Early research (Phase 1)Active Not RecruitingNCT03774654
What this trial is testing

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

Who this might be right for
Refractory B-Cell Non-Hodgkin LymphomaRefractory B-Cell Small Lymphocytic LymphomaRelapsed Adult ALL+2 more
Baylor College of Medicine 13
Very early researchUnknownNCT03672305
What this trial is testing

Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC

Who this might be right for
Primary Hepatocellular Carcinoma
The Second Hospital of Nanjing Medical University 50
Early research (Phase 1)Active Not RecruitingNCT03873805
What this trial is testing

PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer AJCC v8+2 more
City of Hope Medical Center 14
Large-scale testing (Phase 3)Ended earlyNCT05664217
What this trial is testing

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Who this might be right for
Non-Hodgkin LymphomaRelapsed/Refractory Diffuse Large B-cell Lymphoma
Nektar Therapeutics 15
Testing effectiveness (Phase 2)Looking for participantsNCT04422912
What this trial is testing

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Who this might be right for
Pemphigus Vulgaris
Cabaletta Bio 40
Load More Results